Merck stock trades near 52-week highs as Keytruda drives 2026 growth
Published on 08/14/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) stock is trading close to recent highs in mid-August 2026, supported by solid oncology sales and upbeat full-year guidance as investors weigh valuation against growth prospects.
As of August 13, 2026, Merck shares closed at $135.57 on the NYSE, representing a 2.00% gain for that session and placing the stock within a few dollars of its recent 52-week highs, according to a sector overview that shows a last close near $135.59 and a 26.26% gain since the start of 2026. This market summary highlights how the shares have advanced, with the closing price of $135.57 on August 13, 2026 and the CBOE quote at $135.59 reflecting strong recent momentum.
Shares build on a strong year-to-date rally
Recent market data show Merck’s stock up more than 26% year to date as of August 13, 2026, outpacing broader healthcare benchmarks and underscoring investor confidence in the company’s late-stage pipeline and established oncology franchise. A sector ratings snapshot lists the shares at $135.59 with a 3.58% gain over the last five trading days and a 26.26% increase since January 1, 2026, indicating that the recent move is part of a sustained upward trend rather than a short-lived spike.
Intraday quote feeds for August 14, 2026 show the stock trading in the mid-$130s in real time, with one live view displaying Merck at $134.75 in early afternoon Eastern time and another at $135.55, suggesting the shares are consolidating just below the prior close as investors digest recent guidance commentary and oncology sales figures. A live quote and news overview lists Merck at $134.75 with a gain of 1.38% as of 1:28 p.m. EDT on August 14, 2026, while a separate price quote page shows $135.55, underscoring how the stock is trading close to its recent high range rather than pulling back sharply.
Market data for the stock also point to a recent closing price of $135.34 at the end of regular trading at 4:00 p.m. ET on August 13, 2026, accompanied by a daily percentage gain of 1.82%, reinforcing the view that the shares have enjoyed steady upward momentum across multiple venues. One detailed quote feed records the closing level at $135.34 with a 1.82% increase, confirming the consistency of recent price action and supporting the narrative of a strong year-to-date performance in 2026.
Keytruda lifts first half 2026 revenue
Fundamentals for Merck’s oncology portfolio remain a central driver of sentiment in 2026, with flagship immuno-oncology therapy Keytruda generating substantial sales in the first half of the year and helping to underpin the company’s full-year revenue and earnings outlook.
Per an earnings-focused analysis published on August 13, 2026, Keytruda generated $16.40 billion in sales in the first half of 2026, up 4.2% year over year, highlighting continued volume growth despite mounting competition and patent-expiry concerns. The same analysis notes that Merck’s shares have rallied 28.1% year to date, compared with a 14.3% rise for its industry group, underscoring how oncology-led revenue growth has translated into significant share price appreciation.
This outperformance is especially visible when comparing Merck’s year-to-date gain in 2026 against the broader sector and the S&P 500, where the company’s stock has delivered stronger returns over the same period. The valuation overview comments that Merck’s forward price-earnings multiple stands at 18.92 times expected earnings, above an industry average of 18.73 and well above its own five-year mean of 12.86, a premium that investors appear willing to pay for the Keytruda growth story and the broader pipeline.
Keytruda’s global reach continues to expand, and recent regulatory milestones add to its growth narrative. A sector news round-up dated August 14, 2026 reports that earlier in the month Keytruda received Canadian approval for the treatment of muscle-invasive bladder cancer, adding another labeled indication in a challenging disease area and reinforcing the therapy’s profile as a versatile immuno-oncology backbone across multiple tumor types. This sector news item lists the new Canadian approval for muscle-invasive bladder cancer on August 5, 2026 as part of a broader update, signaling ongoing regulatory momentum that can support sustained revenue growth.
Keytruda’s origin as a pioneering immune checkpoint inhibitor is also highlighted in a contemporaneous industry piece, which describes the original product as an immuno-oncology drug developed by MSD and emphasizes its role in reshaping standard-of-care treatment across several cancer indications worldwide. That overview reiterates Keytruda’s position as a core immunotherapy agent, reinforcing the strategic importance of the product in Merck’s portfolio as the company seeks to maintain growth through 2026 and beyond.
Guidance, consensus, and valuation debate for 2026
Investors are increasingly focused on how Merck’s 2026 guidance and consensus earnings estimates align with the current valuation premium, especially as Keytruda approaches key patent dates and the company’s pipeline and business development strategy come under closer scrutiny.
An updated consensus snapshot shows that the 2026 earnings-per-share estimate has been revised downward over the past month, falling from $3.76 to $3.25, while the 2027 estimate has eased from $9.85 to $9.67, suggesting analysts have adjusted their near-term expectations even as the stock has rallied strongly. The earnings estimate discussion frames these revisions in the context of Keytruda’s slowing growth rate, though still positive, and the company’s need to leverage other assets and late-stage candidates to sustain double-digit earnings expansion.
The same consensus review points out that Merck’s forward earnings multiple of 18.92 times is above both the industry average and the company’s historical valuation, raising the question of whether recent share price gains already price in much of the near-term fundamental upside. The valuation metrics put Merck’s forward price-earnings ratio at 18.92 versus an industry average of 18.73 and a five-year mean of 12.86, implying that the market has re-rated the stock higher in anticipation of continued Keytruda expansion and contributions from other pipeline assets.
While the consensus view on earnings has softened slightly, several portfolio updates and sector rating summaries indicate that institutional investors and research coverage remain broadly constructive on Merck’s long-term trajectory, even if nearer-term risk assessments have become more cautious given the high starting valuation. One institutional holding update notes that the company’s shares carry a consensus rating described as a moderate buy and a consensus price target of $135.50, which is almost exactly aligned with the current market price, suggesting that many analysts see the stock as fairly valued based on existing information.
A companion filing summary points to another institutional investor trimming positions, reinforcing that at current levels some holders regard taking profits as prudent while others are still adding exposure based on the company’s defensive qualities and oncology-led growth. That alert reiterates the same moderate buy rating and consensus target of $135.50 from the broader coverage universe, underscoring the divergence between valuation-driven profit-taking and growth-oriented buying as the stock oscillates around target levels.
Insider activity adds another data point
Beyond analyst views and institutional flows, recent insider transactions offer another lens on Merck’s valuation and internal confidence. A Form 4 filing summarised in an insider-trading-focused report shows that Merck’s executive vice president and general counsel, Jennifer Zachary, exercised stock options and sold a meaningful block of shares in mid-August 2026.
The report states that she exercised options for 41,494 shares at an exercise price of $117.89 and 13,433 shares at $84.71, then sold 80,315 common shares on August 12, 2026 at a weighted average price of $133.4557 per share, with the sale occurring in a price range of $133.03 to $133.50. The insider transaction summary highlights that the total value of the shares sold at the weighted average price exceeds $10.7 million, illustrating a sizeable monetization relative to typical insider moves and contributing to the ongoing debate about valuation.
Insider sales do not automatically signal negative sentiment; they can reflect personal diversification or tax planning as much as views on future share price performance. However, when combined with a forward price-earnings premium and consensus earnings downgrades, such activity tends to reinforce the perception that the stock’s near-term upside may be more limited unless Merck delivers positive surprises in upcoming quarters.
Flagship product profile: Keytruda
Merck’s business model in 2026 is heavily influenced by its focus on innovative pharmaceuticals, and Keytruda stands out as a flagship product. This programmed death receptor-1 (PD-1) blocking antibody has become a cornerstone of immuno-oncology treatment, offering durable responses in several cancer types and forming the backbone of many combination regimens.
The therapy’s classification as an immuno-oncology drug developed by MSD is highlighted in a recent industry news piece, which explains that Keytruda’s mechanism of action involves helping the immune system recognize and attack cancer cells more effectively by inhibiting the PD-1 pathway. The description underscores the product’s strategic importance for Merck, as its broad indication base across melanoma, lung cancer, bladder cancer, and other tumor types continues to drive demand even as payers and regulators scrutinize costs.
Keytruda’s recent Canadian approval in muscle-invasive bladder cancer exemplifies its expanding label footprint, enabling Merck to reach additional patient segments and supporting incremental revenue contributions that are particularly meaningful when layered on high existing sales volumes. The sector update notes that the new bladder cancer indication was added on August 5, 2026, which, combined with first half 2026 sales of $16.40 billion and a 4.2% year-over-year growth rate, illustrates the therapy’s continued commercial momentum.
The challenge for Merck is to leverage Keytruda’s success while preparing for eventual competition from biosimilars and alternative immunotherapies as patent protections erode. This dynamic is central to the company’s 2026 guidance strategy, which emphasizes both maximizing existing oncology assets and accelerating the development of next-generation candidates that can deliver diversified revenue streams in the late 2020s.
Stock level and investor takeaway
Merck stock is currently trading on the NYSE in a range around the mid-$130s, with recent verified closing prices at $135.57 and $135.34 on August 13, 2026 and intraday snapshots on August 14, 2026 showing levels between $134.75 and $135.55, reflecting a modest consolidation after a strong year-to-date rally. The closing-price overview and the intraday quote feed both confirm that the shares remain close to their recent highs as investors consider earnings revisions, valuation metrics, and regulatory catalysts.
For investors, the key numerical picture in mid-August 2026 combines a roughly mid-$130s share price and a year-to-date gain exceeding 26%, a forward price-earnings ratio of 18.92 compared with an industry average of 18.73, and Keytruda first half 2026 sales of $16.40 billion that are 4.2% higher than the prior-year period. A comprehensive performance overview ties these figures together, framing Merck as a healthcare company that currently trades at a valuation premium but still offers reasonable growth potential, supported by its oncology franchise and pipeline.
Read more
Investors can find more detailed information on Merck’s strategy, pipeline, and financials in the company’s official investor relations materials at Merck investor relations, which provide full quarterly and annual reports, presentations, and updates on regulatory events relevant to the stock.
Keytruda in everyday treatment practice
Keytruda’s presence in everyday clinical practice is reflected in its broad use across oncology centers worldwide, where physicians integrate the drug into combination regimens tailored to specific tumor biology and patient characteristics. It is often administered alongside chemotherapy, targeted therapies, or other immunotherapies, aiming to boost response rates and extend progression-free survival compared with older standards of care.
From a patient perspective, Keytruda has become one of the most recognized brand names in cancer immunotherapy, representing a shift from purely cytotoxic approaches to targeted immunomodulation. The sustained $16.40 billion in first half 2026 revenue and 4.2% year-over-year growth cited in recent analyses indicate that this real-world adoption remains robust, even as payers adjust formularies and physicians explore newer options.
Merck stock at current levels
At current levels in mid-August 2026, Merck stock trades on the NYSE with recent closing prices in the $135 range and intraday quotes in the mid-$130s, reflecting strong year-to-date appreciation and a valuation premium that hinges on continued Keytruda growth and successful execution of the broader pipeline strategy.
As of August 13, 2026, the closing price of $135.57, combined with a reported 26.26% year-to-date gain and Keytruda first half 2026 sales of $16.40 billion up 4.2% versus the prior year, provides a quantitative snapshot of how the company’s oncology franchise and earnings guidance are intersecting with market expectations for the stock.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Price (as of August 13, 2026, 4:00 p.m. ET): $135.57 USD
Market cap: not specified in the cited sources
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: S&P 500
